Hypothesis

Chronic low‑level ROS emanating from somatic mtDNA heteroplasmy directly suppresses TET2 activity, leading to focal hypermethylation and loss of accessibility at enhancers governing myeloid differentiation and metabolic programs in young hematopoietic stem cells (HSCs).

Experimental Design

1. Model – Generate inducible, HSC‑specific mito‑mutator mice (PolG D257A) crossed with Vav‑Cre‑ERT2; tamoxifen at 8 weeks induces mtDNA mutagenesis without affecting nuclear DNA.
2. Groups – (a) Wild‑type controls, (b) mito‑mutator + vehicle, (c) mito‑mutator + MitoQ (mitochondria‑targeted antioxidant), (d) mito‑mutator + HSC‑specific TET2 overexpression.
3. Readouts – At 4 weeks post‑induction:
   • mtDNA heteroplasmy load by duplex sequencing.
   • Intracellular ROS (MitoSOX) and NADPH oxidase activity.
   • ATAC‑seq and oxidative bisulfite sequencing (oxBS‑seq) on lineage‑negative Sca‑1⁺c‑Kit⁺ (LSK) cells.
   • Colony‑forming unit (CFU) assays and competitive repopulation to assess functional aging.
4. Rescue Test – Compare chromatin accessibility and methylation patterns between groups (c) and (d) to group (b).

Expected Outcomes

• Mito‑mutant HSCs will show a 2‑3‑fold rise in heteroplasmy, elevated mitochondrial ROS, and a significant reduction in ATAC‑seq signal at enhancers of Ppargc1a, Foxo3, and Gata2 (mirroring the inaccessibility seen in aged HSCs) [3][4].
• oxBS‑seq will reveal increased 5‑mC (but not 5‑hmC) at the same loci, indicating TET2 suppression.
• MitoQ or TET2 overexpression will restore accessibility and hydroxymethylation without lowering heteroplasmy, linking ROS‑TET2 axis to chromatin erosion.
• Functional assays will demonstrate rescued CFU output and improved competitive repopulation in rescued groups, while vehicle‑treated mito‑mutants display accelerated hematopoietic decline.

Potential Pitfalls & Alternatives

• Off‑target effects of MitoQ could confound interpretation; include a non‑targeted antioxidant control (NAC) to verify specificity.
• Compensatory upregulation of mitochondrial antioxidant enzymes (e.g., SOD2) might mask ROS rise; measure SOD2 activity and consider SOD2 knock‑down to amplify signal.
• If chromatin changes persist despite ROS scavenging, explore cGAS‑STING activation as a parallel pathway; assess IFN‑stimulated gene expression and test STING inhibitor (H‑151) as an additional rescue.

This framework directly tests whether mtDNA‑derived ROS is a cause rather than a correlate of age‑related chromatin erosion, providing a falsifiable, mechanistic link between the mitochondrial genome and the epigenetic aging program.